Targeted proapoptotic LHRH-BH3 peptide

Pharmaceutical Research

Volumn 20, Issue 6, 2003, Pages 889-896

  Dharap, Sonia S ^a   Minko, Tamara ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Apoptosis; BH3 peptide; Cancer; LHRH peptide

Indexed keywords

GLUTAMINYLHISTIDYLTRYPTOPHYLSERYLTYROSYLGLYCYLLEUCYLARGINYLPROLYLGLYCINE; GLUTAMINYLHISTIDYLTRYPTOPHYLSERYLTYROSYLGLYCYLLEUCYLARGINYLPROLYLGLYCYLG LYC YLMETHIONYLVALYLGLUTAMINYLGLYCYLGLUTAMINYLARGINYLLEUCYLISOLEUCYLALANYLISOLEUCYLA SPARTYLGLYCYLISOLEUCYLARGINYLASPARTYLASPARAGINYLTYROSYLARGININE; GLUTAMINYLHISTIDYLTRYPTOPHYLSERYLTYROSYLGLYCYLLEUCYLARGINYLPROLYLGLYCYLM ETH IONYLGLYCYLGLUTAMINYLVALYLGLYCYLARGINYLGLUTAMINYLLEUCYLALANYLISOLEUCYLISOLEUCYLG LYCYLASPARTYLASPARTYLISOLEUCYLASPARAGINYLARGINYLARGINYLTYROSINE; GONADORELIN; GONADORELIN RECEPTOR; HISTIDYLGLUTAMINYLSERYLTRYPTOPHYLGLYCYLTYROSYLARGINYLLEUCYLGLYCYLPROLYLM ETH IONYLGLYCYLGLUTAMINYLVALYLGLYCYLARGINYLGLUTAMINYLLEUCYLALANYLISOLEUCYLISOLEUCYLG LYCYLASPARTYLASPARTYLISOLEUCYLASPARAGINYLARGINYLARGINYLTYROSINE; METHIONYLGLYCYLGLUTAMINYLVALYLGLYCYLARGINYLGLUTAMINYLLEUCYLALANYLISOLEUC YLI SOLEUCYLGLYCYLASPARTYLASPARTYLISOLEUCYLASPARAGINYLARGINYLARGINYLTYROSINE; PEPTIDE DERIVATIVE; PROTEIN BCL 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; DNA PRIMERS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SPACE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0038015452     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023839319950     Document Type: Article

References (29)

1. F. Bureau, A. Vanderplasschen, F. Jaspar, F. Minner, P. P. Pastoret, M. P. Merville, V. Bours, and P. Lekeux. Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood 99:3683-3691 (2002).
2. S. W. Lowe and A. W. Lin. Apoptosis in cancer. Carcinogenesis 21:485-495 (2000).
3. J. Reed. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:2941-2953 (1999).
4. L. Varriale, E. Crescenzi, V. Paba, B. M. di Celso, and G. Palumbo. Selective light-induced modulation of bcl-XL and bax expressions in indocyanine green-loaded U937 cells: effects of continuous or intermittent photo-sensitization with low IR-light using a 805-nm diode laser. J. Photochem. Photobiol. B 57:66-75 (2000).
5. A. Gross, J. M. McDonnell, and S. Korsmeyer. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899-1911 (1999).
6. R. J. Lutz. Role of the BH3 (BCL-2 homology 3) domain in the regulation of apoptosis and BCL-2-related proteins. Biochem. Sci. Trans. 28:51-56 (2000).
7. R. I. Pakunlu, T. J. Cook, and T. Minko. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 20:351-359 (2003).
8. T. Minko, S. S. Dharap, and A. T. Fabbricatore. Enhancing the efficacy of chemotherapeutic drugs by the suppression of anti-apoptotic cellular defense. Cancer Detect. Prev. in press
9. E. Holinger, T. Chittenden, and R. J. Lutz. Bak BH3 peptides antagonize BCL-XL functions and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 274:13298-13304 (1999).
10. L. Vieira, P. Boya, I. Cohen, C. El Hamel, D. Haouzi, S. Druillenec, A. S. Belzacq, C. Brenner, B. Roques, and G. Kroemer. Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-X(L). Oncogene 21:1963-1977 (2002).
11. T. Minko, S. S. Dharap, B. I. Pakunlu, and J. L. Colaizzi. Advanced drug delivery systems in cancer chemotherapy. Dis. Manage Clin. Outcomes 3:48-54 (2001).
12. C. Grundker, A. R. Gunthert, R. P. Millar, and G. Emons. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab. 87:1427-1430 (2002).
13. P. Volker, C. Grundker, O. Schmidt, K. D. Schulz, and G. Emons. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol. 186:171-179 (2002).
14. T. Minko, P. Kopeckova, V. Pozharov, and J. Kopecek. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54:223-233 (1998).
15. T. Minko, P. Kopeckova, and J. Kopecek. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:986-996 (1999).
16. T. Minko, P. Kopeckova, and J. Kopecek. Preliminary evaluation of caspase-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control. Release 71:227-237 (2001).
17. T. Minko, P. V. Paranjpe, B. Qiu, A. Lallo, R. Won, S. Stein, and P. J. Sinko. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 50:143-150 (2002).
18. A. D. Schimmer, D. W. Hedley, S. Chow, N. A. Pham, A. Chakrabartty, D. Bouchard, T. W. Mak, M. R. Trus, and M. D. Minden. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 8:725-733 (2001).
19. M. Walsh, R. J. Lutz, T. G. Cotter, and R. O'Connor. Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood 99:3439-3448 (2002).
20. T. Minko, P. Kopeckova, and J. Kopecek. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86:108-117 (2000).
21. G. V. Putcha, C. A. Harris, K. L. Moulder, R. M. Easton, C. B. Thompson, and E. M. Johnson Jr. Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J. Cell Biol. 157:441-453 (2002).
22. X. M. Zhou, Y. Liu, G. Payne, R. J. Lutz, and T. Chittenden. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J. Biol. Chem. 275: 25046-25051 (2000).
23. X. Roucou, T. Rostovtseva, S. Montessuit, J. C. Martinou, and B. Antonsson. Bid induces cytochrome c-impermeable Bax channels in liposomes. Biochem. J. 363:547-552 (2002).
24. J. Chai, C. Du, J. W. Wu, S. Kyin, X. Wang, and Y. Shi. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406:855-862 (2000).
25. C. Du, M. Fang, Y. Li, L. Li, and X. Wang. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42 (2000).
26. M. Baum. A vision for the future? Br. J. Cancer 85(Suppl 2):15-18 (2001).
27. M. Nowicki, G. Adamkiewicz, W. Bryc, and F. Kokot. The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma. Am. J. Obstet. Gynecol. 186:340-344 (2002).
28. Y. Wang, H. Matsuo, O. Kurachi, and T. Maruo. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur. J. Endocrinol. 146:447-456 (2002).
29. A. Wells, J. C. Souto, J. Solava, J. Kassis, K. J. Bailey, and T. Turner. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin. Cancer Res. 8:1251-1257 (2002).